|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's range||76.36 - 77.85|
|52-week range||25.00 - 87.65|
|PE ratio (TTM)||10.77|
|Earnings date||7 Feb 2018|
|Forward dividend & yield||3.30 (3.40%)|
|1y target est||85.19|
For 3Q17, revenues from established prescription products fell 6.5% YoY (year-over-year) at constant exchange rates to 2.26 billion euros.
Sanofi’s diabetes and cardiovascular franchises include the blockbuster diabetes drug Lantus, which contributes ~70% of all revenues for diabetes products.
Sanofi's Sanofi Genzyme franchise includes specialty care product revenues and reported revenue growth of 12.5% to 1.63 billion euros.
A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Sanofi: In a note titled "Unicorn sighted", Barclays sees co's valuation back at more reasonable levels ...
Sanofi’s 3Q17 earnings were released on November 2, 2017. It reported revenues of 9.05 billion euros for 3Q17, an operational growth of 4.7% YoY.
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général ...
Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.
Sanofi, Principia agree to develop multiple sclerosis drug candidate Clinical-stage oral drug candidate (PRN2246) with the potential to treat multiple sclerosis Principia to receive $40 million upfront ...
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
Regeneron (REGN) is trading higher Friday, thanks to an upgrade from Robert W. Baird. Analysts Brian Skorney and Neena Bitritto-Garg boosted their rating on the stock from Sell to Neutral, with a $408 price target. In addition, Skorney writes that he is encouraged by the sales that Sanofi (SNY) reported for its eczema treatment Dupixent yesterday, which it sells in partnership with Regeneron.
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis ...
Sanofi's (SNY) Q3 results were mixed as it reported in-line earnings and missed sales expectations. Meanwhile, the outlook for the Diabetes franchise remains weak.
On a per-share basis, the Paris-based company said it had net income of 73 cents. Earnings, adjusted for non-recurring costs, came to $1 per share. The results met Wall Street expectations. The average ...
Sanofi confirmed its 2017 outlook after it posted slightly lower-than-expected third-quarter results, and gave a more precise range on expectations of a sales decline at its embattled diabetes business. The French drugmaker said currency-adjusted sales at its diabetes franchise would likely shrink by 6-8 percent per year between 2015 and 2018. Third-quarter business net income fell 1.1 percent at constant exchange rates to 2.141 billion euros ($2.5 billion).
French biotech company Sanofi said that its third-quarter net profit fell 6.4%, despite a slight uptick in sales for vaccines amid continued weakness in its diabetes and cardiovascular business.
Wall Street analysts estimate that Sanofi's (SNY) 3Q17 revenues will fall ~2.2% to 9.44 billion euros as compared to 9.65 billion euros in 3Q16.